 DUBLIN, Ohio--BUSINESS WIRE--Navidea Biopharmaceuticals, Inc. NYSE American: NAVB Navidea or the Company, a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the Company has submitted its formal Type B Meeting Request to the FDA. The FDA has granted the Type B meeting and has requested submission of the Briefing Book. The FDA will now review the Companys formal briefing documents containing results from the NAV 